Use of lipoic acid for improving the bioavailability of mineral salts
AssigneeBASF SE
InventorsKlaus Krämer, Martin Jochen Klatt
Life of this patent
Estimating the term…
Abstract
The use of α-lipoic acid or α-dihydrolipoic acid for increasing the bioavailability of mineral salts, the use of α-lipoic acid or α-dihydrolipoic acid in combination with metal salts, in particular the use of metal α-lipoates, metal α-dihydrolipoates or metal-α-lipoic acid complexes, in particular in mineral preparations or drugs and the metal α-lipoates, metal α-dihydrolipoates or metal-α-lipoic acid complexes themselves are described.
Claims17
A method of increasing the bioavailabilty of mineral salts which comprises combining said salts and α-lipoic acid or α-dihydrolipoic acid.
A composition comprising (R)-α-lipoic acid and at least one mineral salt selected from the group consisting of Fe, Cr, Co and Mn salts.
A metal α-lipoate, metal α-dihydrolipoate or metal-α-lipoic acid complex of the formula II′,
- (M)w(Lp)x(A)y(H2O)z II′
- where
- M is a metal cation selected from the group consisting of cations of Fe, Cr, Co and Mn,
- Lp is racemic α-lipoic acid or α-dihydrolipoic acid, (R)- or (S)-α-lipoic acid or (R)- or (S)-α-dihydolipoic acid, racemic α-lipoate or dihydro-α-lipoate or (R)- or (S)-α-lipoate or (R)- or (S)-dihydro-α-lipoate,
- A is a physiologically acceptable monovalent or divalent anion,
- w is 1 or 2,
- x is 1, 2, 3 or 4,
- y is 0, 1, 2, 3, 4, 5 or 6,
- where the subscripts w, x and y correspond to the valency and charge equalization and
- the following compounds are excluded:
- Mn(Lip−)ClO4, FE2DHLrac2-)3,
- where
- Lip− is monovalent negative racemic or (R)- or (S)-α-lipoate,
- Liprac++ is monovalent negative racemic α-lipoate,
- Liprac is racemic α-lipoic acid and
- DHLrac2++—is divalent negative racemic α-dihydrolipoate.
Dependencies are inferred from the claim text.